Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Depomed Inc (DEPO)

Depomed Inc (DEPO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Depomed Inc 7999 GATEWAY BLVD. SUITE 300 NEWARK CA 94560 USA

www.depomedinc.com P: 510-744-8000

Description:

Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once- daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. ProQuin XR extended-release tablets have been approved by the FDA for the once-daily treatment of uncomplicated urinary tract infections and are currently being marketed in the United States. In addition, once-daily Glumetza has been approved for use in adults with type two diabetes and is currently being marketed in the United States and Canada. The company is currently evaluating Gabapentin GR for the treatment of two pain indications, postherpetic neuralgia and diabetic peripheral neuropathy, and menopausal hot flashes.

Key Statistics

Overview:

Market Capitalization, $K 466,616
Shares Outstanding, K 63,920
Annual Sales, $ 380,720 K
Annual Net Income, $ -102,500 K
Last Quarter Sales, $ 63,270 K
Last Quarter Net Income, $ -21,050 K
60-Month Beta 1.27
% of Insider Shareholders 2.27%
% of Institutional Shareholders 98.87%

Growth:

1-Year Return 19.09%
3-Year Return -74.61%
5-Year Return 1.39%
5-Year Revenue Growth 319.20%
5-Year Earnings Growth -137.74%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.19 on 08/08/18
Latest Earnings Date N/A
Earnings Per Share ttm -0.48
EPS Growth vs. Prev Qtr -168.75%
EPS Growth vs. Prev Year 23.26%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

DEPO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -13.22%
Return-on-Assets % -2.52%
Profit Margin % -26.92%
Debt/Equity 3.21
Price/Sales 1.21
Price/Cash Flow 8.58
Price/Book 2.39
Book Value/Share 3.01
Interest Coverage -0.41
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar